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O. Castillo1,2, H. Rojas3,4, Z. Domínguez5, E. Anglés-Cano6,7 and R. Marchi1*Abstract
Background: Fibrin provides a temporary matrix at the site of vascular injury. The aims of the present work were
(1) to follow fibrin formation and lysis onto the surface of human dermal microvascular endothelial cells (HMEC-1),
and (2) to quantify the secretion of fibrinolytic components in the presence of fibrin.
Methods: Fibrin clots at different fibrinogen concentrations were formed on top of (model 1) or beneath (model 2)
the endothelial cells. Fibrin formation or lysis onto the surface of HMEC-1 cells, was followed by turbidity. Clot structure
was visualized by laser scanning confocal microscopy (LSCM). The secretion of uPA and PAI-1 by HMEC-1 cells
was quantified by ELISA.
Results: The rate of fibrin formation increased approximately 1.5-fold at low fibrinogen content (0.5 and 1 mg/mL;
p < 0.05) compared to the condition without cells; however, it was decreased at 2 mg/mL fibrinogen (p < 0.05) and no
differences were found at higher fibrinogen concentrations (3 and 5 mg/mL). HMEC-1 retarded dissolution of clots
formed onto their surface at 0.5 to 3 mg/mL fibrinogen (p < 0.05). Secretion of uPA was 13 × 10−6 ng/mL per cell in the
absence of RGD and 8 × 10−6 ng/mL per cell in the presence of RGD, when clots were formed on the top of HMEC-1.
However, the opposite was found when cells were grown over fibrin: 6 × 10−6 ng/mL per cell without RGD vs. 17 × 10−6
ng/mL per cell with RGD. The secretion of PAI-1 by HMEC-1 cells was unrelated to the presence of fibrin or RGD, 7 × 10−6
μg/mL per cell and 5 × 10−6 μg/mL per cell, for the apical (model 1) and basal clots (model 2), respectively.
Conclusions: HMEC-1 cells influence fibrin formation and dissolution as a function of the fibrin content of clots.
Clot degradation was accentuated at high fibrin concentrations. The secretion of fibrinolytic components by
HMEC-1 cells seemed to be modulated by integrins that bind RGD ligands.
Keywords: Fibrinogen, Fibrin, Fibrinolysis, Urokinase-type plasminogen activator, Plasminogen activator inhibitor
type 1, Endothelium, Human dermal microvascular endothelial cellsBackground
Fibrinogen is a 340 kDa plasma glycoprotein that circulates
at approximately 2–4 mg/mL. The molecule is 45 nm long
and comprises a symmetrical dimer consisting of two outer
D domains and a central E domain, linked by α- helical
coiled-coil rods. The fibrinogen molecule consists of two
sets of three different polypeptide chains Aα, Bβ, and γ,
joined by disulphide bonds at their N-termini E domain.
The C-termini of the Bβ and γ chains are located in the D
domain, while that of the Aα chains form a free non well-
structured domain, the αC domain [1].* Correspondence: rmarchi@ivic.gob.ve
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International License (http://creativecommons
reproduction in any medium, provided you g
the Creative Commons license, and indicate if
(http://creativecommons.org/publicdomain/zeFibrinogen does not polymerize spontaneously due to
negative charges repulsion at the N-termini of the Aα-
and Bβ- chains. The removal by thrombin of short peptide
sequences at Aα A1-R16 (fibrinopeptide A, FpA) and Bβ
Q1-R14 (fibrinopeptide B, FpB) triggers the association
between the fibrin monomers (fibrinogen molecules
devoid of FpA and FpB) [1, 2]. The release of fibrino-
peptides A and B exposes the polymerization sites “A”
(knob A) and “B” (knob B), which associate to constitu-
tive polymerization sites located at the C-termini end
of the γ chains (“a” or hole a) and β (“b” or hole b). The
association of fibrin monomers give rise to protofibrils
that have two monomer units of width. The lateral ag-
gregation of protofibrils forms the fibrin fibers. It seemsis distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
ro/1.0/) applies to the data made available in this article, unless otherwise stated.
Castillo et al. BMC Hematology  (2016) 16:9 Page 2 of 9that FpBs release contribute to the lateral aggregation
of protofibrils [3–5].
Coagulation and fibrinolysis are activated simultan-
eously in response to injury. The cross-linked fibrin is
deposited in blood vessels and tissues, and plasmin is re-
sponsible of the soluble fibrin degradation products [6].
Under physiological conditions, activators, inhibitors, and
cofactors finely regulated fibrinolysis. Plasmin is formed
from its precursor (plasminogen, Pg) by tissue type
plasminogen activator (tPA) at the surface of fibrin [7].
Furthermore, endothelial cells are involved in fibrinolysis
regulation by secreting substances, such as tPA and
plasminogen activator inhibitor type 1 (PAI-1). Although
tPA is a poor plasminogen activator in solution, at the
surface of fibrin the reaction is amplified approximately
two orders of magnitude [7, 8].
Fibrin network structure depends on the quality and
amount of fibrinogen, on thrombin and calcium concen-
trations, and on ionic strength, among others [9, 10].
The fibrin meshwork structure is characterized by fibrin
thickness, fiber density, pores size, and rigidity that re-
flects fibrin FXIIIa cross-linking and clot structure [11].
It has been found that clots from patients with throm-
botic disorders were composed by thin fibers with
increased fibrin density and rigidity, and decreased clot
lysis rate [12–14]. Endothelial cells (ECs) interact with
fibrin at the sites of vascular injury, thrombosis, inflam-
mation and tumour growth, whereas they are quiescent
when exposed to circulating fibrinogen [15]. The
regulation of fibrinolysis by the endothelium has been
widely studied [16–19]; however, the response of ECs
to different fibrin structures has not been explored as
yet. This knowledge can be relevant in thrombotic or
bleeding mechanisms.
In the present work, fibrin clots of different structure
were prepared at varying fibrinogen concentrations.
Fibrin polymerization and fibrinolysis onto the HMEC-
1 surface were followed by turbidity. Furthermore,
fibrin association to ECs receptors was visualized by
LSCM in the presence and absence of the synthetic
disintegrin RGD.
Methods
Materials
The MCDB 131 medium, foetal bovine serum, penicillin,
streptomycin, fungizone, L-glutamine were purchased from
GIBCO (Grand Island, NY, USA). Epidermal growth factor
was from Invitrogen (Nalge Nunc International, Rochester,
NY, USA). The 96 well microtiter plates and the 8 wells
LabTek® Chamber Slide™ from Nalge Nunc International
(Rochester, NY, USA). Lysine-sepharose was purchased
from Health Care (Piscataway, NJ, USA). Bovine thrombin
and RGD peptide were from Sigma (St Louis, MO. USA).
The dyes di-8-anepps and Alexa 488 were from MolecularProbes (Eugene, OR, USA). FluoSpheres size kit # 1 carb-
oxylate modified microspheres red fluorescent was from
Molecular Probes (Eugene, OR, USA). The uPA and PAI-1
ELISA kits were purchased from American Diagnostica
(Greenwich, Connecticut, USA).
Endothelial cells culture
The human dermal microvascular endothelial cells
(HMEC-1) were kindly donated by Dr. Edwin Ades,
Department of Health and Human Services Centers
for Disease Control and Prevention (CDC, Atlanta
USA). The cells were cultivated with MCDB 131 medium
supplemented with 10 % foetal bovine serum, penicillin 100
U/mL, streptomycin 100 μg/mL, L-glutamine 200 mM, and
epidermal growth factor 10 ng/mL. For polymerization and
fibrinolysis experiments, cells were plated in 96 wells
microtiter plates, and for confocal microscopy experiments
in 8 wells LabTek® Chamber Slide™. Cells were cultivated at
37 °C in a humid atmosphere with 5 % CO2 until ~80 %
confluence. The optimal quantity of thrombin to be used in
order to clot fibrinogen without affecting cell morphology
and viability was standardized. After cells reached ~80 %
confluence, 1 to 5 nM thrombin was incubated on the
surface of the cells monolayer during 2 h. The cells’ morph-
ology was observed with an optical microscope (unchanged
at 1 nM; results not shown). Similarly, the number of cells
to be seeded in the microplate wells and confocal micros-
copy chambers were previously standardized in order to
obtain 80 % confluence overnight.
Fibrinogen purification
Fibrinogen was purified from pooled human plasma
obtained from healthy donors. The Ethics Committee of
the Instituto Venezolano de Investígaciones Científicas
(IVIC) approved the project, and all subjects signed an
informed consent before blood withdrawal. Blood was
collected in citrate (1 volume of 0.13 M trisodium citrate
and 9 volumes of blood). Immediately centrifuged at
2500 × g during 20 min, at 4 °C. Fibrinogen was precipi-
tated by salting out using β-alanine, essentially as de-
scribed elsewhere [20]. The plasminogen was removed
from fibrinogen preparation using a lysine-sepharose
column, following the manufacturer’s instructions. The
clottability of the purified fibrinogen was >90 %.
Fibrin polymerization and fibrinolysis on HMEC-1
The HMEC-1 cells (100,000 cells/well) were seeded on
96-well microtiter plate and cultivated overnight. The
following day the medium was discarded and the fibrin
meshwork was formed on top of the cells. Clots directly
formed on the plastic surface of the microtiter plate
served as controls. In an Eppendorf tube 143 μL of
purified fibrinogen (0.5–5 mg/mL, final), 40 μL MCDB
131 non-supplemented medium and 17.5 μL of bovine
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were mixed and immediately transferred on the top of
the cells or directly on the plastic well surface. The
optical density (OD) was read every 2 min during
100 min at 350 nm in an Infinite 200 M (Tecan, Vienna,
Austria). For each curve it was calculated the slope
(mOD/s)×100 and the maximum absorbance (MaxAbs,
mOD). Experiments were run at least three times by tripli-
cate. Fibrinolysis was triggered by the addition of 100 nM
Pg and 0.145 nM tPA (previously standardized) to fibrino-
gen solutions (0.5–3 mg/mL) before clotting with thrombin
– CaCl2. The OD was recorded every minute until the OD
reached baseline values. For each curve it was measured
the time needed to decrease by 50 % the maximum absorb-
ance (T50; s), the lysis rate, in the descending part of the
curve (LR; mOD/s)×100; and the area under the curve
(AUC; mOD × s). Experiments were run at least three
times by duplicate.
At the end of each experiment the morphology of the
cells was checked with an optical microscope.
Fibrin interaction with HMEC-1
Cells (120,000) were seeded in LabTek glass chamber
slide and maintained at 37 °C in a humid atmosphere
with 95 % air and 5 % CO2 and grown-up to 80 %
confluence. The culture medium was removed and cells
were labelled with 4 μM di-8-anepps for 15 min. The
cells were then washed three times with phosphate
buffered-saline (PBS). Fibrinogen (0.5, 2, and 5 mg/mL)
mixed with 1 mM RGD (or the equivalent volume of
buffer) and Alexa Fluor 488-labeled fibrinogen (19 μg/
206 μL sample volume), was clotted with 1 nM throm-
bin – 2 mM CaCl2 (final). The clotting mixture was
immediately transferred over the cells or directly to the
bottom of the glass chamber (control, without cells).
Clot formation was allowed to progress for 2 h in a tis-
sue culture incubator. Finally, the clot’s surface was cov-
ered with supplemented medium without serum.
Duplicates of each condition were performed at least in
three independent experiments.
In order to discard that the interaction of fibrin with
the cells was merely an adsorption phenomenon, 2 μm
fluorescent microspheres were included in the reaction
mixture before adding thrombin.
The clot structure on the surface of HMEC-1 was visu-
alized using a Nikon Eclipse TE 2000-U laser microscope
(with a 488 nm Argon or 543 nm HeNe laser). The object-
ive used was Plan Apo VC 60X in water immersion with a
work distance of 0.27. The acquisition pinhole was set to
60 μm. For each clot several fields were examined at ran-
dom before digital recording. Five areas of 212 × 212 μm
(x,y) were selected from each duplicate. A Z- stack was
imaged from the bottom of the dish (0 μm) to different
distances from the surface of the cells, with step sizes of0.5 μm. The fibers diameter and density were measured
from the volume render obtained with the Olympus
FV10-ASW 2.1, and peak analysis from OriginPro 8.
Urokinase-type plasminogen activator (uPA) and
plasminogen activator inhibitor 1 (PAI-1) secretion by
HMEC-1 in the presence of fibrin
Fibrinogen was polimerized on the top of a HMEC-1 cul-
ture (model 1) or the cells were grown on fibrin as substra-
tum (model 2). In model 1, fibrin was formed on HMEC-1
cells (100,000) using different fibrinogen concentration
(0.25, 0.5, 1, 1.5, 2, 3, and 5 mg/mL). Clots were allowed to
form during 30 min in the incubator and 200 μL of
medium without serum was then added. The supernatant
was carefully collected after 12 h and stored at −80 °C until
use. The following protocol was used with RGD: a cell
monolayer was incubated during 3 h with 1 mM RGD pre-
pared in supplemented MCDB 131 medium. The medium
was then discarded and the cells washed with PBS. A fibrin
reaction mixture with 1 mM RGD was added on the top
of the cells. The basal condition consisted of the cell
monolayer incubated during 12 h with supplemented
MCDB 131 medium.
In order to cultivate the HMEC-1 on a fibrin layer
(model 2), thin fibrin films of 30 μL were formed on the
bottom of the 96-well microplate, using the same clotting
condition as model 1. After 30 min at 37 °C, 100,000 cells/
well supplemented or not with 1 mM RGD were seeded
on the top of the fibrin and the plate left overnight in the
incubator. The following day fresh medium without serum
was added, and incubated for 12 h. The supernatant was
collected and kept at −80 °C until use. Experiments were
performed in triplicate and uPA and PAI-1 concentrations
were measured in the cell supernatant by ELISA. The
basal condition consisted of the cells monolayer incubated
during 12 h with supplemented MCDB 131 medium.
The quantity of uPA and PAI-1 secreted was normalized
to the number of cells per well.
Statistical analysis
Statistical analysis was performed with OriginPro version
8.1. Descriptive statistics: mean, standard deviation (SD)
or the standard error of the mean (SEM) were calculated.
Normality was assessed by Shapiro-Wilk Test. Means
were compared by one-way-ANOVA. A significance level
of 0.05 was used.
Results
Fibrin polymerization and fibrinolysis on the top of
HMEC-1
The slope and MaxAbs increase steadily from 0.5 to
5 mg/mL both when fibrin was formed on the top of
HMEC monolayer or without cells (Table 1). Figure 1
shows the time course of fibrin formation at 3 different
Table 1 Summary of the kinetics of fibrin polymerization on the top of HMEC-1 at different fibrinogen concentrations
Fibrin + Cells Fibrin
Fg (mg/mL) Slope (mOD/s)×100 MaxAbs (mOD) Slope (mOD/s)×100 MaxAbs (mOD)
0.5 50 ± 7* 305 ± 20* 33 ± 4 221 ± 14
1 83 ± 3* 494 ± 16* 61 ± 2 406 ± 10
2 111 ± 5* 976 ± 45 132 ± 11 1019 ± 58
3 519 ± 59 1715 ± 42 668 ± 154 1543 ± 179
5 710 ± 37 1890 ± 113* 710 ± 103 1657 ± 82
Results are expressed as the mean (± SD)
Fg fibrinogen, MaxAbs maximum absorbance
*p < 0.05 Comparison between fibrin polymerization parameters of clots formed on the top of the cells with those performed in its absence
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influence of fibrinogen concentration on the kinetics of
fibrin polymerization is clearly evidenced. In the
presence of cells MaxAbs was higher compared to the
condition without cells. Fibrinolysis results are summa-
rized in Table 2. The lysis rate (LR) was slightly but
significantly decreased in the presence of cells at the
fibrinogen concentrations tested (0.5 to 3 mg/mL). How-
ever, the time needed for 50 % of clot lysis (T50%) was
similar. In Fig. 2 are shown the time course of fibrinoly-
sis at 1, 2, and 3 mg/mL fibrinogen.
Fibrin interaction with HMEC-1
Fibrin network formed at three different fibrinogen
concentrations (0.5, 2, and 5 mg/mL) on the top of
HMEC-1 monolayers were digitized near the cell surface
and at 15 μm, both in the presence and absence of
1 mM of the synthetic peptide RGD that competes with
fibrinogen for integrin-ligand binding. In Fig. 3 it is
clearly seen that at 0.5 and 2 mg/mL the fibrin fibersFig. 1 Fibrin polymerization on the top of HMEC-1 at different
fibrinogen concentrations. Filled symbols represent the condition
of fibrin formed on the top of the cells and empty symbols clots
formed directly on the plastic dish. (■, □): 1 mg/mL, (▲, △):
3 mg/mL and (★, ☆): 5 mg/mLinteracted profoundly with the cell surface, the fibers
looked radially stressed and the colocalization (in yellow)
of the fibrin (green) with the cells membrane (red) is
evidenced. However, at 5 mg/mL the interaction with the
cell surface was rather decreased. This peculiar fibrin
fibers distribution disappears with distance from the cell
surface. At approximately 15 μm, the fibers looked
uniformly distributed. When RGD was added to the
fibrinogen solutions, the interaction between fibrin and
cells decreased.
In order to rule out that the fibrin association to the
cells was merely an adsorption phenomenon, fluorescent
microspheres of 2 μm were incorporated into the
clotting mixture. The fibrin fibers did not interact with
the beads nor looked stressed, confirming that fibrin
fibers are interacting with specific receptors on the cell
membrane (Fig. 4).
The fibrin network was characterized by measuring fi-
brin fiber diameter and fibrin density near the cell surface
and at 15 μm (Table 3). Fibrin fibers were thicker near the
cell surface compared to that observed at 15 μm at all fi-
brinogen concentrations tested without RGD. In contrast,
in the presence of RGD there was not such relationship.
Apparently, only at 5 mg/mL the fibrin fibers diameter did
not change. Fibrin density was greater near the cell surface
both in the presence or absence of RGD, except at
0.5 mg/mL in the presence of RGD (p > 0.05).
Changes in fluorescence intensity as a function of the
distance from the cell surface at 2 mg/mL of fibrinogen
is shown in Fig. 5.
HMEC-1 secretion of uPA and PAI-1 in the presence of fibrin
The basal secretion of uPA was 7.0 ± 0.5×10−6 ng/mL
per cell and that of PAI-1 6.7 ± 0.5×10−6 μg/mL per cell.
Since the secretion of uPA and PAI-1 was almost similar
at the different fibrinogen concentrations tested in the
presence or not of RGD, these values were averaged and
reported in Table 4. In model 1, when fibrin was formed
on the top of the cells monolayer, uPA secretion in the
absence of RGD was ~2-fold higher than in its presence
(p < 0.05). However, the opposite was found for model 2.
Table 2 Summary of the fibrin degradation on the top of HMEC-1
Fibrin + Cells Fibrin
Fg (mg/mL) T50% (s) LR (mOD/s) ×100 AUC (mODxs) ×106 T50% (s) LR (mOD/s) ×100 AUC (mODxs) ×106
0.5 870 ± 79 41 ± 4* 0.3230 ± 0.0204 820 ± 17 48 ± 2 0.2946 ± 0.0147
1 1790 ± 173 58 ± 0.8* 1.5004 ± 0.1617 1650 ± 60 77 ± 2 1.4120 ± 0.0843
2 4330 ± 466 54 ± 2.3* 7.5957 ± 0.0927* 4150 ± 69 68 ± 1.4 6.8737 ± 0.2645
3 5860 ± 259 77 ± 21* 19.6071 ± 1.0103* 5690 ± 193 135 ± 1.4 16.1075 ± 1.0519
Results are expressed as the mean (± SD)
Fg fibrinogen, T50% time required to decrease the MaxAbs 50 %, LR lysis rate, AUC area under the curve
*p < 0.05 Comparison between fibrin degradation parameters of clots formed on the top of the cells with those performed in its absence
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the secretion of uPA in the absence of RGD was decreased
2-fold (p < 0.05). The secretion of PAI-1 in model 1 was
1.3-fold higher compared to model 2 (p < 0.05). The PAI-1
concentration in the presence of fibrin was comprised in
the 95 % CI of HMEC-1 basal secretion.
Discussion
The aims of the present work were (1) to study fibrin
formation and lysis onto the surface of HMEC-1 cells,
and (2) to quantify uPA and PAI-1 secretion in the pres-
ence of fibrin. We also analyzed the fibrin meshwork
formed on the top of HMEC-1 cells by laser scanning
confocal microscopy. The structure of fibrin was modu-
lated by modifying the concentration of fibrinogen.
Fibrin is pro inflammatory, pro-angiogenic and may
contribute to the development of inflammatory disease
processes and tumorigenesis [21–23]. Atherogenesis is a
multifactorial process and the atherosclerotic lesions
may be initiated by the interaction of fibrin with the
endothelium [24]. In normal physiologic conditions, the
endothelium displays antiplatelet, anticoagulant and
fibrinolytic properties [25].Fig. 2 Fibrin degradation on the top of HMEC-1 at different fibrinogen
concentrations followed by turbidity. (■, □): 1 mg/mL, (▲,△): 2 mg/
mL and (★,☆): 3 mg/mL. Filled symbols: fibrin formed on the top of
the cells; empty symbols: clots formed directly on the plastic dishIn order to measure the secretion of fibrinolytic
components from HMEC-1 we have used an adhesion
model, where HMEC-1 cells were seeded directly on the
plastic surface and after reaching 80 % of confluence
fibrin was formed on their top (model 1) or cells were
grown on a fibrin film (model 2).
The type of plasminogen activator secreted by HMEC-
1 has been differently reported in the literature [26–28].
However, a majority of reports [29–31], including those
from the group of Angles-Cano [26, 32, 33], have clearly
demonstrated, using methods that identify either the mo-
lecular mass (Western blot) or the activity of the molecular
mass (fibrin or casein zymography) that only uPA (54 kDa)
is detected in culture media or lysates from HMEC-1. We
have verified that the HMEC-1 line used in these studies
secretes uPA (lysis band at 54 kDa by zymography).
Similar to what has been found for other ECs cultured
in vitro, HMEC-1 basal PAI-1 secretion was higher than
uPA, approximately 1000-fold [34–36]. In model 1, with-
out RGD, the amount of uPA secreted to the medium
was 2-fold higher compared to the basal secretion and
to model 2. This difference was attributed to the avail-
ability of thrombin. In model 1, at the beginning of
fibrin formation, thrombin is in solution and directly in
contact with the cells, while in model 2 fibrin was
already gelled, and less thrombin was accessible to the cells.
The response of the ECs to thrombin depends on their
origin, in human umbilical vein endothelial cells (HUVEC)
the quantity of tPA and PAI-1 is dose-dependent on
thrombin concentration, but not in human omental tissue
microvascular endothelial cells (HOTMC) [35].
During fibrin formation from 0.5, 1, and 5 mg/mL
fibrinogen the OD increased faster in the presence of
HMEC-1 than without it (p < 0.05). Tietze et al. found
similar results with human mesothelial cells (HOMC) but
at constant fibrinogen concentration [34]. This “catalytic”
cell effect at low fibrinogen concentration may be an
advantage for patients with hypofibrinogenemia, which
could contribute to stop faster blood extravasation. The
rate of fibrin degradation in the presence of HMEC-1 was
significantly decreased at all fibrin concentration (0.5 to
3 mg/mL), reaching a maximum value at 3 mg/mL (2-fold
less). These results were attributed to several factors. The
Fig. 3 Laser scanning confocal microscopy images of clots formed
on the top of HMEC-1 at different fibrinogen concentrations. The
fibrin fibers were visualized with Alexa 488 and the cell membrane
with di-8-anepps. The pictures show the fibrin fibers arrangements
of clots supplemented or not with 1 mM RGD near the cell surface
at 0.5, 2 and 5 mg/mL fibrinogen, and at 15 μm away. The tool bar
represents 20 μm
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cell) could decrease both the functional availability of uPA
and tPA (externally added tPA), although the tPA bound
to fibrin is less susceptible to PAI-1 inactivation [7, 37].
The peculiar fibrin structure observed near the cell surface
could impair clot dissolution. In general, fibrin network
with increased fibers density are digested slower [38].
However, opposite results were found with HOMC, where
the T50% was decreased in the presence of cells [34]. The
results reported by these authors were intriguing, since
clots formed without cells were totally degraded earlier
than those in the presence of cells.
It was previously found that fibrin fibers forms clumps
near the surface of HUVEC culture; however, at 50 μm this
pattern disappear and they distributed homogeneously [39].
The integrin involved in this interaction was the αvβ3 [39].
This integrin binds the ligand at specific RGD sequences of
different adhesive proteins such as fibronectin, vitronectin,
fibrinogen, among others [40]. In the present work the
fibrin network structure formed at different fibrinogen con-
centrations was analyzed by LSCM. As expected, increasing
the fibrinogen concentration increases the fibrin density
[41], and the fibers associated to the cell surface lookedFig. 4 Fibrin network formed with fluorescent microspheres. A field
with only one bead was magnified in order to appreciate that these
particles did not interact with fibers. The tool bar represents 2 μm
Table 3 Characterization of fibrin networks formed on the surface
of HMEC-1 culture by laser scanning confocal microscopy (LSCM)
Fibers diameter (μm)
Fg (mg/mL) - RGD Near - RGD Far + RGD Near + RGD Far
0.5 2.02 ± 0.05* 1.65 ± 0.05 1.49 ± 0.09* 1.72 ± 0.07
2 1.98 ± 0.12* 1.76 ± 0.12 1.99 ± 0.06* 1.62 ± 0.07
5 2.03 ± 0.65* 1.52 ± 0.33 2.00 ± 0.10 1.95 ± 0.33
Fibrin density (peaks/μm)
Fg (mg/mL) - RGD Near - RGD Far + RGD Near + RGD Far
0.5 0.192 ± 0.052* 0.099 ± 0.045 0.205 ± 0.051 0.160 ± 0.054
2 0.299 ± 0.029* 0.135 ± 0.035 0.270 ± 0.023* 0.152 ± 0.030
5 0.254 ± 0.030* 0.141 ± 0.057 0.282 ± 0.022* 0.138 ± 0.056
Fibrin fibers diameter and density were quantified from LSCM images
Values are expressed as mean (± SEM) of 3 experiments performed in duplicate
*p < 0.05. Comparisons are between near the cells surface vs. far, without (−)
and with (+) RGD
Fig. 5 Representation of the changes of the mean fluorescence
intensity according to the distance from the bottom of the dish up to
40 μm. a Without and with RGD at 2 mg/mL fibrinogen. b Without cells
at 0.5, 2 and 5 mg/mL fibrinogen
Table 4 HMEC-1 cells secrete urokinase-type plasminogen
activator and plasminogen activator inhibitor type 1
μg/mL per cell Model 1 Model 2
uPA×10−9 (−RGD) 12.7*,** (11.2–14.1) 6.2* (5.0–7.4)
uPA×10−9 (+RGD) 7.5** (5.9–9.1) 17.3 (15.0–19.6)
PAI-1×10−6 (−RGD) 7.87** (6.65–9.10) 5.97 (4.50–7.44)
PAI-1×10−6 (+RGD) 7.38** (6.54–8.23) 5.08 (3.01–7.16)
Urokinase and PAI-1 were quantified by ELISA in HMEC conditioned-medium
obtained in the presence of fibrin. Fibrin was formed on the top of the cells
monolayer (model 1) or cells were seeded on the top of fibrin film (model 2).
The basal secretion of uPA was 7.0 ± 0.5 × 10−9 μg/mL per cell, and that of
PAI-1 6.7 ± 0.5 × 10−6 μg/mL per cell. The quantity of uPA and PAI-1 secreted
was normalized to the number of cells. Results are expressed as the mean and
the 95 % confidence interval (CI) in brackets
*p < 0.05 uPA secretion without RGD (−RGD) compared to that with RGD
(+RGD) for model 1
**p < 0.05 uPA secretion without RGD of model 1 compared to that of model
2, and with RGD in model 1 compared to that in model 2
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works at a given fibrinogen concentration [39, 42, 43].
Interestingly, at high fibrinogen concentration (5 mg/mL)
the interaction of fibrin with the cells was decreased.
Indeed, at increasing fibrin content, the number of
protofibrils per fiber are greater [44], probably diminishing
the accessibility of the RGD sites on the fibrin fibers
(Aα 572–575) to integrins [40, 45].
The changes in fibrin fiber diameter at varying fibrino-
gen concentrations were not clearly appreciated by LSCM
in spite of the low thrombin concentration used. This is
probably due to the lower resolution limit of LSCM
(~200–400 nm).Conclusions
We demonstrated that HMEC-1 influenced fibrin forma-
tion as a function of the fibrinogen input. However, the
rate of fibrin degradation in the presence of HMEC-1 was
significantly decreased at all fibrin concentrations.
Impairment of fibrin binding to its cell receptor by RGD
influenced the secretion of fibrinolytic components thus
suggesting a role for fibrin binding in this mechanism.
The next step would be to investigate the signalling
pathway involved in the αvβ3 integrin activation, probably
coupled to thrombin. A limitation of our study is that the
results were obtained using HMEC-1 cells and may
therefore be pertinent only to this cell line.Abbreviations
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